JP2018522540A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018522540A5 JP2018522540A5 JP2017563165A JP2017563165A JP2018522540A5 JP 2018522540 A5 JP2018522540 A5 JP 2018522540A5 JP 2017563165 A JP2017563165 A JP 2017563165A JP 2017563165 A JP2017563165 A JP 2017563165A JP 2018522540 A5 JP2018522540 A5 JP 2018522540A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- sequences
- light chain
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012634 fragment Substances 0.000 claims description 74
- 239000000427 antigen Substances 0.000 claims description 69
- 102000036639 antigens Human genes 0.000 claims description 69
- 108091007433 antigens Proteins 0.000 claims description 69
- 101000893585 Homo sapiens Growth/differentiation factor 2 Proteins 0.000 claims description 45
- 102000046041 human GDF2 Human genes 0.000 claims description 37
- 108091033319 polynucleotide Proteins 0.000 claims description 26
- 102000040430 polynucleotide Human genes 0.000 claims description 26
- 239000002157 polynucleotide Substances 0.000 claims description 26
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 14
- 125000000539 amino acid group Chemical group 0.000 claims description 12
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 12
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- 150000007523 nucleic acids Chemical group 0.000 claims description 11
- 208000019423 liver disease Diseases 0.000 claims description 9
- 229940124597 therapeutic agent Drugs 0.000 claims description 9
- 108010040422 Bone Morphogenetic Protein Receptors Proteins 0.000 claims description 8
- 102000001893 Bone Morphogenetic Protein Receptors Human genes 0.000 claims description 8
- 102100040892 Growth/differentiation factor 2 Human genes 0.000 claims description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 8
- 102000010571 Type II Bone Morphogenetic Protein Receptors Human genes 0.000 claims description 7
- 108010063130 Type II Bone Morphogenetic Protein Receptors Proteins 0.000 claims description 7
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 6
- 239000004148 curcumin Substances 0.000 claims description 4
- 208000010706 fatty liver disease Diseases 0.000 claims description 4
- 230000005764 inhibitory process Effects 0.000 claims description 4
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims description 3
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 208000018565 Hemochromatosis Diseases 0.000 claims description 3
- 241000711549 Hepacivirus C Species 0.000 claims description 3
- 241000700721 Hepatitis B virus Species 0.000 claims description 3
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims description 3
- 208000018839 Wilson disease Diseases 0.000 claims description 3
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims description 3
- 230000007882 cirrhosis Effects 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 102000039446 nucleic acids Human genes 0.000 claims description 3
- 108020004707 nucleic acids Proteins 0.000 claims description 3
- 208000007232 portal hypertension Diseases 0.000 claims description 3
- 201000000742 primary sclerosing cholangitis Diseases 0.000 claims description 3
- 208000010157 sclerosing cholangitis Diseases 0.000 claims description 3
- 239000003053 toxin Substances 0.000 claims description 3
- 231100000765 toxin Toxicity 0.000 claims description 3
- 101000695367 Homo sapiens Bone morphogenetic protein 10 Proteins 0.000 claims description 2
- 101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 claims description 2
- 101000899361 Homo sapiens Bone morphogenetic protein 7 Proteins 0.000 claims description 2
- 101100175311 Mus musculus Gdf2 gene Proteins 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 102000052974 human BMP10 Human genes 0.000 claims description 2
- 102000045896 human BMP2 Human genes 0.000 claims description 2
- 102000046107 human BMP7 Human genes 0.000 claims description 2
- 229940127121 immunoconjugate Drugs 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 102000005962 receptors Human genes 0.000 claims description 2
- 108020003175 receptors Proteins 0.000 claims description 2
- 206010067125 Liver injury Diseases 0.000 claims 1
- 241000282567 Macaca fascicularis Species 0.000 claims 1
- 210000000941 bile Anatomy 0.000 claims 1
- 231100000753 hepatic injury Toxicity 0.000 claims 1
- 230000035800 maturation Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 102100034111 Activin receptor type-1 Human genes 0.000 description 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 2
- 102100025423 Bone morphogenetic protein receptor type-1A Human genes 0.000 description 2
- 101000799140 Homo sapiens Activin receptor type-1 Proteins 0.000 description 2
- 101000934638 Homo sapiens Bone morphogenetic protein receptor type-1A Proteins 0.000 description 2
- 101100490437 Mus musculus Acvrl1 gene Proteins 0.000 description 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 2
- -1 dacratasvir Chemical compound 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- GPTFURBXHJWNHR-UHFFFAOYSA-N protopine Chemical compound C1=C2C(=O)CC3=CC=C4OCOC4=C3CN(C)CCC2=CC2=C1OCO2 GPTFURBXHJWNHR-UHFFFAOYSA-N 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 208000037221 Hepatic congestion Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229960001997 adefovir Drugs 0.000 description 1
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000003510 anti-fibrotic effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 229960000980 entecavir Drugs 0.000 description 1
- YXPVEXCTPGULBZ-WQYNNSOESA-N entecavir hydrate Chemical compound O.C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)C1=C YXPVEXCTPGULBZ-WQYNNSOESA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- AFLFKFHDSCQHOL-IZZDOVSWSA-N gft505 Chemical compound C1=CC(SC)=CC=C1C(=O)\C=C\C1=CC(C)=C(OC(C)(C)C(O)=O)C(C)=C1 AFLFKFHDSCQHOL-IZZDOVSWSA-N 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229960001627 lamivudine Drugs 0.000 description 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- ZXERDUOLZKYMJM-ZWECCWDJSA-N obeticholic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)CCC(O)=O)CC[C@H]21 ZXERDUOLZKYMJM-ZWECCWDJSA-N 0.000 description 1
- 229960001601 obeticholic acid Drugs 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229960002091 simeprevir Drugs 0.000 description 1
- JTZZSQYMACOLNN-VDWJNHBNSA-N simeprevir Chemical compound O=C([C@@]12C[C@H]1\C=C/CCCCN(C)C(=O)[C@H]1[C@H](C(N2)=O)C[C@H](C1)OC=1C2=CC=C(C(=C2N=C(C=1)C=1SC=C(N=1)C(C)C)C)OC)NS(=O)(=O)C1CC1 JTZZSQYMACOLNN-VDWJNHBNSA-N 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229960002935 telaprevir Drugs 0.000 description 1
- BBAWEDCPNXPBQM-GDEBMMAJSA-N telaprevir Chemical compound N([C@H](C(=O)N[C@H](C(=O)N1C[C@@H]2CCC[C@@H]2[C@H]1C(=O)N[C@@H](CCC)C(=O)C(=O)NC1CC1)C(C)(C)C)C1CCCCC1)C(=O)C1=CN=CC=N1 BBAWEDCPNXPBQM-GDEBMMAJSA-N 0.000 description 1
- 108010017101 telaprevir Proteins 0.000 description 1
- 229960004556 tenofovir Drugs 0.000 description 1
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical group OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2015080887 | 2015-06-05 | ||
| CNPCT/CN2015/080887 | 2015-06-05 | ||
| PCT/IB2016/053095 WO2016193872A2 (en) | 2015-06-05 | 2016-05-26 | Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018522540A JP2018522540A (ja) | 2018-08-16 |
| JP2018522540A5 true JP2018522540A5 (enExample) | 2019-06-06 |
Family
ID=56096674
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017563165A Pending JP2018522540A (ja) | 2015-06-05 | 2016-05-26 | 骨形成タンパク質９（ｂｍｐ９）を標的とする抗体およびそれらのための方法 |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US10047155B2 (enExample) |
| EP (1) | EP3303387A2 (enExample) |
| JP (1) | JP2018522540A (enExample) |
| KR (1) | KR20180014714A (enExample) |
| CN (1) | CN107614526A (enExample) |
| AR (1) | AR104906A1 (enExample) |
| AU (1) | AU2016273028B2 (enExample) |
| BR (1) | BR112017021484A2 (enExample) |
| CA (1) | CA2982237A1 (enExample) |
| CL (1) | CL2017002705A1 (enExample) |
| CO (1) | CO2017011512A2 (enExample) |
| CR (1) | CR20170554A (enExample) |
| EA (1) | EA201792561A1 (enExample) |
| EC (1) | ECSP17080733A (enExample) |
| HK (1) | HK1249537A1 (enExample) |
| IL (1) | IL254837A0 (enExample) |
| MX (1) | MX2017015690A (enExample) |
| PE (1) | PE20180041A1 (enExample) |
| PH (1) | PH12017502020A1 (enExample) |
| SG (1) | SG11201707815RA (enExample) |
| TN (1) | TN2017000417A1 (enExample) |
| TW (1) | TW201716438A (enExample) |
| UY (1) | UY36706A (enExample) |
| WO (1) | WO2016193872A2 (enExample) |
| ZA (1) | ZA201805721B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11299751B2 (en) | 2016-04-29 | 2022-04-12 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| WO2017189959A1 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| CN106994181A (zh) * | 2017-03-10 | 2017-08-01 | 上海交通大学医学院附属第九人民医院 | Bmp9在制备延缓肝纤维化药物中的应用 |
| CN107760779B (zh) * | 2017-11-03 | 2020-10-16 | 中国医学科学院阜外医院 | 肺动脉高压相关的突变型bmp9基因及其应用 |
| IL293894A (en) | 2019-12-20 | 2022-08-01 | Novartis Ag | Combination treatment of liver diseases using integrin inhibitors |
| WO2022101853A1 (en) | 2020-11-16 | 2022-05-19 | Novartis Ag | Method of determining liver fibrosis |
| KR102780923B1 (ko) * | 2021-10-22 | 2025-03-17 | 고려대학교 산학협력단 | Bmp 유래 신규 펩타이드 및 이의 용도 |
| WO2023233330A1 (en) | 2022-05-31 | 2023-12-07 | Pfizer Inc. | Anti-bmp9 antibodies and methods of use thereof |
| CN115040638A (zh) * | 2022-06-14 | 2022-09-13 | 上海市东方医院（同济大学附属东方医院） | Bmp9在制备mafld、nash、nash相关肝纤维化/肝硬化的药物中的用途 |
| CN116058335B (zh) * | 2022-11-25 | 2025-07-25 | 中国医学科学院阜外医院 | 一种自发强直性脊柱炎模型的构建方法和应用 |
| CN116115736A (zh) * | 2022-12-09 | 2023-05-16 | 上海交通大学医学院附属瑞金医院 | 一种bmp9在制备抑制成骨细胞衰老的制剂或药物中的应用 |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (134)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| JPS60500673A (ja) | 1983-03-08 | 1985-05-09 | コモンウエルス セラム ラボラトリ−ズ コミツシヨン | 抗原活性を有するアミノ酸配列 |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US5013653A (en) | 1987-03-20 | 1991-05-07 | Creative Biomolecules, Inc. | Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage |
| DE3856559T2 (de) | 1987-05-21 | 2004-04-29 | Micromet Ag | Multifunktionelle Proteine mit vorbestimmter Zielsetzung |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| US5336603A (en) | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
| US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| KR900005995A (ko) | 1988-10-31 | 1990-05-07 | 우메모또 요시마사 | 변형 인터류킨-2 및 그의 제조방법 |
| WO1990006952A1 (fr) | 1988-12-22 | 1990-06-28 | Kirin-Amgen, Inc. | Facteur de stimulation de colonies de granulocytes modifies chimiquement |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5112946A (en) | 1989-07-06 | 1992-05-12 | Repligen Corporation | Modified pf4 compositions and methods of use |
| FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
| WO1991006570A1 (en) | 1989-10-25 | 1991-05-16 | The University Of Melbourne | HYBRID Fc RECEPTOR MOLECULES |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| WO1991010741A1 (en) | 1990-01-12 | 1991-07-25 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US5349053A (en) | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| KR100246529B1 (ko) | 1990-12-14 | 2000-04-01 | 스티븐 에이. 서윈. 엠.디. | 수용체 관련된 신호 변환 경로를 위한 키메라 사슬 |
| AU652472B2 (en) | 1991-06-25 | 1994-08-25 | Genetics Institute, Llc | BMP-9 compositions |
| US6287816B1 (en) | 1991-06-25 | 2001-09-11 | Genetics Institute, Inc. | BMP-9 compositions |
| DE69233745D1 (de) | 1991-12-02 | 2008-10-23 | Cambridge Antibody Tech | Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken |
| EP0571613B1 (en) | 1991-12-13 | 2003-09-17 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| EP0746609A4 (en) | 1991-12-17 | 1997-12-17 | Genpharm Int | NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| FR2686901A1 (fr) | 1992-01-31 | 1993-08-06 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant. |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
| AU4116793A (en) | 1992-04-24 | 1993-11-29 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| DE69330523T4 (de) | 1992-08-21 | 2012-08-23 | Vrije Universiteit Brussel | Immunoglobuline ohne leichte ketten |
| CA2161351C (en) | 1993-04-26 | 2010-12-21 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
| SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
| US5834252A (en) | 1995-04-18 | 1998-11-10 | Glaxo Group Limited | End-complementary polymerase reaction |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| NZ292124A (en) | 1994-07-29 | 1998-10-28 | Smithkline Beecham Plc | Il-4 antagonist comprising a fusion of a mutant il-4-antibody fragment |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| US6423501B2 (en) | 1996-12-13 | 2002-07-23 | Beth Israel Deaconess Medical Center | Calcium-independent negative regulation by CD81 of receptor signaling |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US6034062A (en) | 1997-03-13 | 2000-03-07 | Genetics Institute, Inc. | Bone morphogenetic protein (BMP)-9 compositions and their uses |
| AU736549B2 (en) | 1997-05-21 | 2001-08-02 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Method for the production of non-immunogenic proteins |
| ES2231991T3 (es) | 1997-06-11 | 2005-05-16 | Borean Pharma A/S | Modulo de trimerizacion. |
| CA2293632C (en) | 1997-06-12 | 2011-11-29 | Research Corporation Technologies, Inc. | Artificial antibody polypeptides |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| PT2180007E (pt) | 1998-04-20 | 2013-11-25 | Roche Glycart Ag | Engenharia de glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
| DK2270147T4 (da) | 1999-04-09 | 2020-08-31 | Kyowa Kirin Co Ltd | Fremgangsmåde til at kontrollere aktiviteten af immunologisk funktionelt molekyle |
| DE19932688B4 (de) | 1999-07-13 | 2009-10-08 | Scil Proteins Gmbh | Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen |
| PT1144607E (pt) | 1999-07-20 | 2009-04-22 | Morphosys Ag | Novos métodos para apresentar (poli)peptídeos/ proteínas em partículas bacteriofágicas através de ligações dissulfureto |
| AU784012B2 (en) | 1999-08-24 | 2006-01-12 | E. R. Squibb & Sons, L.L.C. | Human CTLA-4 antibodies and their uses |
| EP1278767A4 (en) | 2000-04-12 | 2003-11-12 | Principia Pharmaceutical Corp | ALBUMIN FUSED PROTEINS |
| WO2002057445A1 (en) | 2000-05-26 | 2002-07-25 | National Research Council Of Canada | Single-domain brain-targeting antibody fragments derived from llama antibodies |
| ATE446366T1 (de) | 2000-06-22 | 2009-11-15 | Genentech Inc | Agonistische monoklonale antikörper gegen trkc |
| CN101940189A (zh) | 2000-11-30 | 2011-01-12 | 米德列斯公司 | 用于生产人类抗体的转基因转染色体啮齿动物 |
| US20040175756A1 (en) | 2001-04-26 | 2004-09-09 | Avidia Research Institute | Methods for using combinatorial libraries of monomer domains |
| US20050053973A1 (en) | 2001-04-26 | 2005-03-10 | Avidia Research Institute | Novel proteins with targeted binding |
| US20050048512A1 (en) | 2001-04-26 | 2005-03-03 | Avidia Research Institute | Combinatorial libraries of monomer domains |
| WO2002092780A2 (en) | 2001-05-17 | 2002-11-21 | Diversa Corporation | Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof |
| WO2003035835A2 (en) | 2001-10-25 | 2003-05-01 | Genentech, Inc. | Glycoprotein compositions |
| AU2002357060A1 (en) | 2001-12-03 | 2003-06-17 | Abgenix, Inc. | Antibody categorization based on binding characteristics |
| US20030157579A1 (en) | 2002-02-14 | 2003-08-21 | Kalobios, Inc. | Molecular sensors activated by disinhibition |
| US7335478B2 (en) | 2002-04-18 | 2008-02-26 | Kalobios Pharmaceuticals, Inc. | Reactivation-based molecular interaction sensors |
| AU2003217912A1 (en) | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
| US7816497B2 (en) | 2002-10-30 | 2010-10-19 | University Of Kentucky | Compositions and methods for inhibiting drusen complement components C3a and C5a for the treatment of age-related macular degeneration |
| WO2004072266A2 (en) | 2003-02-13 | 2004-08-26 | Kalobios Inc. | Antibody affinity engineering by serial epitope-guided complementarity replacement |
| DE10324447A1 (de) | 2003-05-28 | 2004-12-30 | Scil Proteins Gmbh | Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin |
| JP4851327B2 (ja) | 2003-09-02 | 2012-01-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 上皮−間葉移行に関与するサイトカイン |
| US7968690B2 (en) | 2003-12-23 | 2011-06-28 | Rinat Neuroscience Corp. | Agonist anti-trkC antibodies and methods using same |
| US7981843B2 (en) | 2004-01-20 | 2011-07-19 | Kalobios Pharmaceuticals, Inc. | Antibody specificity transfer using minimal essential binding determinants |
| EP1571159A1 (en) | 2004-03-04 | 2005-09-07 | Bayerische Julius-Maximilians-Universität Würzburg | Mutein of a bone morphogenetic protein and use thereof |
| US20060008844A1 (en) | 2004-06-17 | 2006-01-12 | Avidia Research Institute | c-Met kinase binding proteins |
| DE602005018789D1 (de) | 2004-08-10 | 2011-05-26 | Cardiff Biolog Ltd | Verfahren und kit zur prognose von brustkrebs |
| JP4696237B2 (ja) | 2005-03-03 | 2011-06-08 | 国立大学法人 岡山大学 | 糖尿病性腎症の治療用医薬組成物 |
| PL2447283T3 (pl) | 2005-09-07 | 2015-12-31 | Amgen Fremont Inc | Ludzkie przeciwciała monoklonalne przeciwko kinazie podobnej do receptora aktywiny-1 (ALK-1) |
| JPWO2007034753A1 (ja) | 2005-09-22 | 2009-03-26 | 恵一 福田 | コンドロモジュリン−ｉを有効成分とする血管新生関連疾患治療剤 |
| CN1844391A (zh) | 2006-04-26 | 2006-10-11 | 嘉兴波亿生物科技开发有限公司 | 人骨形态发生蛋白9重组蛋白质核苷酸序列及生产方法和用途 |
| MX363905B (es) | 2006-06-12 | 2019-04-08 | Aptevo Res & Development Llc | Proteinas de union multivalentes monocatenarias con funcion efectora. |
| EP1873157A1 (en) | 2006-06-21 | 2008-01-02 | Bayer Schering Pharma Aktiengesellschaft | Pyrazolopyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same |
| US8088895B2 (en) | 2006-10-18 | 2012-01-03 | Chemocentryx, Inc. | Antibodies that bind CXCR7 epitopes |
| US8642031B2 (en) * | 2006-11-02 | 2014-02-04 | Acceleron Pharma, Inc. | Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof |
| EP3181580A1 (en) | 2006-11-02 | 2017-06-21 | Acceleron Pharma Inc. | Alk1 receptor and ligand antagonists and uses thereof |
| JP2008225463A (ja) | 2007-02-14 | 2008-09-25 | Asahi Kasei Chemicals Corp | 積層光学フィルム |
| EP2140005B1 (en) | 2007-03-19 | 2013-12-11 | National Research Council of Canada | Fusion proteins comprising two tgf-beta binding domains |
| US20090017019A1 (en) | 2007-06-01 | 2009-01-15 | Wyeth | Methods and compositions for modulating bmp-10 activity |
| EP2291401A2 (en) | 2008-05-15 | 2011-03-09 | Acceleron Pharma, Inc. | Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof |
| WO2010126169A1 (ja) * | 2009-04-30 | 2010-11-04 | 協和発酵キリン株式会社 | Alk1阻害剤を有効成分とする血管障害を抑制するための医薬組成物 |
| ES2656232T3 (es) | 2009-05-08 | 2018-02-26 | Novartis Ag | Métodos de modulación de fibrosis usando moduladores de la proteína morfogenética ósea 9 (BMP-9) |
| US20160228509A9 (en) * | 2009-05-08 | 2016-08-11 | Novartis Ag | Diagnostic BioMarkers for Fibrotic Disorders |
| KR101767860B1 (ko) | 2010-08-20 | 2017-08-14 | 와이어쓰 엘엘씨 | 디자이너 골형성 단백질 |
| SG188328A1 (en) | 2010-09-03 | 2013-04-30 | Stem Centrx Inc | Novel modulators and methods of use |
| FR2971250A1 (fr) | 2011-02-07 | 2012-08-10 | Univ Nantes | Anticorps anti-gb3 utiles dans le traitement des maladies associees a l'angiogenese |
| MX2014009277A (es) | 2012-02-02 | 2015-03-03 | Acceleron Pharma Inc | Antagonistas alk1 y sus usos en el tratamiento de carcinoma de celula renal. |
| US9809636B2 (en) | 2012-04-06 | 2017-11-07 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels comprising administering BMP9 |
| BR112014027291A2 (pt) | 2012-05-02 | 2017-08-08 | Symphogen As | composições de anticorpos pan-her humanizados |
| CN103387605B (zh) | 2012-05-08 | 2018-06-12 | 复旦大学 | 一种rtn4b多肽、其单抗、产生单抗的杂交瘤细胞株及他们的制备与应用 |
| WO2014007198A1 (ja) * | 2012-07-02 | 2014-01-09 | 協和発酵キリン株式会社 | 抗ｂｍｐ９抗体を有効成分とする、腎性貧血、がん性貧血などの貧血に対する治療剤 |
| FR2993278B1 (fr) | 2012-07-13 | 2016-02-19 | Coatex Sas | Utilisation d'un polymere peigne pour preparer une suspension contenant du carbonate de calcium et presentant une sensibilite a la temperature reduite. |
| JPWO2014051109A1 (ja) | 2012-09-28 | 2016-08-25 | 協和発酵キリン株式会社 | 抗ヒトｂｍｐ９抗体および該抗体を有効成分とする異所性骨化疾患の治療剤 |
| EA202090707A1 (ru) * | 2013-10-25 | 2020-12-30 | Акселерон Фарма, Инк. | Эндоглиновые пептиды для лечения фиброзных заболеваний |
-
2016
- 2016-05-26 EA EA201792561A patent/EA201792561A1/ru unknown
- 2016-05-26 AU AU2016273028A patent/AU2016273028B2/en not_active Ceased
- 2016-05-26 JP JP2017563165A patent/JP2018522540A/ja active Pending
- 2016-05-26 US US15/165,150 patent/US10047155B2/en not_active Expired - Fee Related
- 2016-05-26 BR BR112017021484A patent/BR112017021484A2/pt not_active Application Discontinuation
- 2016-05-26 KR KR1020177034690A patent/KR20180014714A/ko not_active Withdrawn
- 2016-05-26 PE PE2017002522A patent/PE20180041A1/es unknown
- 2016-05-26 HK HK18109109.9A patent/HK1249537A1/zh unknown
- 2016-05-26 SG SG11201707815RA patent/SG11201707815RA/en unknown
- 2016-05-26 MX MX2017015690A patent/MX2017015690A/es unknown
- 2016-05-26 EP EP16726435.7A patent/EP3303387A2/en not_active Withdrawn
- 2016-05-26 CN CN201680032467.1A patent/CN107614526A/zh active Pending
- 2016-05-26 WO PCT/IB2016/053095 patent/WO2016193872A2/en not_active Ceased
- 2016-05-26 CA CA2982237A patent/CA2982237A1/en not_active Abandoned
- 2016-05-26 TN TNP/2017/000417A patent/TN2017000417A1/en unknown
- 2016-05-28 CR CR20170554A patent/CR20170554A/es unknown
- 2016-06-02 UY UY0001036706A patent/UY36706A/es not_active Application Discontinuation
- 2016-06-03 AR ARP160101663A patent/AR104906A1/es unknown
- 2016-06-04 TW TW105117773A patent/TW201716438A/zh unknown
-
2017
- 2017-10-02 IL IL254837A patent/IL254837A0/en unknown
- 2017-10-25 CL CL2017002705A patent/CL2017002705A1/es unknown
- 2017-11-07 PH PH12017502020A patent/PH12017502020A1/en unknown
- 2017-11-09 CO CONC2017/0011512A patent/CO2017011512A2/es unknown
- 2017-12-05 EC ECIEPI201780733A patent/ECSP17080733A/es unknown
-
2018
- 2018-07-05 US US16/027,954 patent/US20190153084A1/en not_active Abandoned
- 2018-08-27 ZA ZA201805721A patent/ZA201805721B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018522540A5 (enExample) | ||
| JP2024150751A5 (enExample) | ||
| JP2018535650A5 (enExample) | ||
| JP7654346B2 (ja) | 多重特異性抗体およびその使用 | |
| JP2019528083A5 (enExample) | ||
| JP2018502060A5 (enExample) | ||
| JP2018516537A5 (enExample) | ||
| TW201124427A (en) | IL-1 binding proteins | |
| JP2017531642A5 (enExample) | ||
| KR20230016186A (ko) | 갈렉틱-3 차단에 의한 염증성 질환의 치료 방법 | |
| KR20150131360A (ko) | ＴＮＦα에 대해 지시된 이원 특이적 결합 단백질 | |
| JP2011528902A5 (enExample) | ||
| JP2012504955A5 (enExample) | ||
| MX2014008101A (es) | Proteinas de union especificas duales dirigidas contra il-13 y/o il-17. | |
| JP2016538876A5 (enExample) | ||
| CN112165974B (zh) | 乙型肝炎抗体 | |
| AU2014248636B2 (en) | Humanized anti-N2 antibodies | |
| JP2010520290A5 (enExample) | ||
| JPWO2019209995A5 (enExample) | ||
| WO2017059813A1 (zh) | 抗乙肝表面抗原的抗体及其用途 | |
| JP2023516195A (ja) | Ｃ１９ ｃ３８二特異性抗体 | |
| JP2020505350A5 (enExample) | ||
| TW202342095A (zh) | 用於治療和預防ｃｏｖｉｄ—１９之組成物 | |
| JP2021520854A (ja) | 黄熱を処置するための方法および組成物 | |
| JPWO2021042019A5 (enExample) |